NCT01381536View on ClinicalTrials.gov

Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

July 20, 2010

Primary Completion Date

November 27, 2010

Study Completion Date

November 27, 2010

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

GSK1550188 1mg/kg or 10mg/kg

IV one shot

Trial Locations (2)

812-0025

GSK Investigational Site, Fukuoka

982-0032

GSK Investigational Site, Miyagi

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01381536 - Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE) | Biotech Hunter | Biotech Hunter